Covalon Technologies Ltd. (OTCMKTS:CVALF) Sees Significant Decline in Short Interest

Covalon Technologies Ltd. (OTCMKTS:CVALF) was the target of a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 17,648 shares, a decline of 46.6% from the June 30th total of 33,048 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 3,660 shares, the short-interest ratio is currently 4.8 days.

Covalon Technologies Price Performance

OTCMKTS CVALF opened at $1.55 on Wednesday. The company has a 50-day simple moving average of $1.52 and a two-hundred day simple moving average of $1.39. Covalon Technologies has a 12-month low of $1.16 and a 12-month high of $2.14. The firm has a market cap of $42.81 million, a price-to-earnings ratio of 38.76 and a beta of 0.63.

Covalon Technologies (OTCMKTS:CVALF) last announced its quarterly earnings data on Thursday, May 21st. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.02. The firm had revenue of $6.27 million for the quarter, compared to analysts’ expectations of $6.70 million. Covalon Technologies had a return on equity of 5.77% and a net margin of 5.05%.

Covalon Technologies Company Profile

Covalon Technologies Ltd. (OTCMKTS:CVALF) is a Canadian medical device and life sciences company specializing in advanced wound care and infection prevention solutions. Based in Toronto, Ontario, Covalon leverages proprietary photochemical bonding technology to create antimicrobial and anti-adhesion polymer coatings for a range of medical devices and wound dressings. The company’s core focus is on reducing surgical site infections and improving healing outcomes through innovative biomaterials.

The company’s product portfolio comprises hydrogel-based wound dressings and polymer-coated medical device components.